Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Böblingen – page 73

944 clinical trials in Böblingen, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Böblingen at a glance
944
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

944 trials in Böblingen

Open in trial search

Study of Giredestrant Combined with Pertuzumab-Trastuzumab (Phesgo) for Patients with Previously Untreated HER2-Positive, Estrogen Receptor-Positive Locally Advanced or Metastatic Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:F. Hoffmann-La Roche AG

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Institut Für Frauengesundheit GmbH

Study on Long-term Effects and Safety of Odevixibat in Children with Biliary Atresia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Odevixibat
  • Sponsor:Ipsen Pharma

Study on Botensilimab and Balstilimab for Patients with Advanced Melanoma Resistant to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Balstilimab
  • Sponsor:Agenus Inc.

Study of Pembrolizumab and Cisplatin for Patients with Stage III-IVA Resectable Head and Neck Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Renal cell carcinoma

Not recruiting

Study on the Safety and Effectiveness of Pembrolizumab for Patients with Kidney Cancer After Surgery

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab as Additional Treatment for Patients with High-Risk Locally Advanced Cutaneous Squamous Cell Carcinoma After Surgery and Radiation

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Neoplasm

Not recruiting

Study of Pembrolizumab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Chemotherapy for Patients with Triple Negative Breast Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Venetoclax and Azacitidine for Adults 18+ with Acute Myeloid Leukemia Not Eligible for Standard Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:University of Leipzig

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Böblingen

What the registry says about research in the country

01 Neurological Disorders

Groundbreaking research focusing on multiple sclerosis treatments, including studies comparing new therapies like fenebrutinib and frexalimab with established treatments. Several trials are investigating novel approaches for both relapsing and primary progressive forms of MS.

  • Relapsing Multiple Sclerosis
  • Primary Progressive MS
  • Brain Inflammation

Additional studies explore innovative treatments for migraine prevention in patients who haven't responded to conventional therapies.

02 Mental Health Studies

Comprehensive research into major depressive disorder and schizophrenia, evaluating new therapeutic approaches. Trials include testing novel compounds for depression with anhedonia and long-term safety studies for schizophrenia treatments.

  • Depression Treatment
  • Schizophrenia Management
  • ADHD Therapy

Studies also examine new formulations for ADHD treatment in adults, comparing immediate and modified-release medications.

03 Oncology Research

Innovative trials in breast cancer treatment, particularly focusing on HER2-negative and triple-negative variants. Studies evaluate both neoadjuvant and adjuvant therapeutic approaches.

  • Triple-Negative Breast Cancer
  • HER2-Negative Breast Cancer
  • Rectal Cancer

Additional research examines treatment strategies for locally advanced rectal cancer, comparing pre- and post-surgical interventions.

04 Neurodegenerative Conditions

Critical research into Alzheimer's disease and related conditions, with studies focusing on treating associated symptoms like psychosis and agitation in dementia patients.

  • Alzheimer's Psychosis
  • Dementia Management
  • Behavioral Symptoms

These trials aim to improve quality of life for patients with neurodegenerative disorders through targeted symptom management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.